Funds will be used to advance pre-clinical and manufacturing development programmes and prepare for clinical studies. Leeds, UK, 13 May 2021: LUNAC Therapeutics (LUNAC), a

Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with paroxysmal nocturnal

Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action

Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at

New UK company backed by Epidarex Capital emerges from stealth Cambridge, UK, March 23, 2021 – Dunad Therapeutics (“Dunad”) emerges today to develop next-generation small

Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements

Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE

Leeds, UK, 5 February 2021:  LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants, has been named